Ghost Generics: 505(b)(2) Approved Medications - On Demand
Participants will learn to Identify products approved via the 505(b)(2) NDA pathway and how they differ from generic molecules and explain recent Centers for Medicare & Medicaid Services (CMS) coding changes for reimbursement of 505(b)(2) approved products. They will also become aware of the financial and operational challenges regarding 505(b)(2) approved products and discuss practice considerations
Target Audience
- Pharmacists
- Pharmacy Technicians
- Other Healthcare Professionals
Learning Objectives
At the conclusion of this activity, pharmacists should be able to:
- Identify products approved via the 505(b)(2) NDA pathway and how they differ from generic molecules
- Explain recent Centers for Medicare & Medicaid Services (CMS) coding changes for reimbursement of 505(b)(2) approved products
- Discuss financial and operational challenges regarding 505(b)(2) approved products and discuss practice considerations
At the conclusion of this activity, pharmacy technicians should be able to:
- Identify products approved via the 505(b)(2) NDA pathway and how they differ from generic molecules
- Explain recent Centers for Medicare & Medicaid Services (CMS) coding changes for reimbursement of 505(b)(2) approved products
- Discuss financial and operational challenges regarding 505(b)(2) approved products and discuss practice considerations
FACULTY & PLANNERS
Carolyn Liptak, MBA, BS Pharm
Pharmacy Executive Director
Vizient, Inc.
Dmitry Walker, PharmD, MS
Director of Oncology and Investigation Drug Pharmacy Services
West Virginia University
Lubna Mazin
Pharmacy Revenue Cycle Manager
Children's Hospital Colorado
Francie Carney, RPh, MHA
Manager of Pharmacy Revenue Integrity
MedVenta (Novant Health Enterprises)
Tyler Wood, PharmD, BCBBS
System Director for Pharmacy Oncology & Biosimilars
Providence St. Josephs Health
Stacy Lauderdale, PharmD, BCPS
Associate Vice President of Evidence-Based Medicine and Drug Information
Vizient, Inc.
Jackie Stokes, BBS
Pharmacy Services Manager
Vizient, Inc.
Samantha Gordon, MS
CE Programs Manager
Vizient, Inc.
Marilu Kelly, MSN, RN, NPD-BC, CHCP
Director, Continuing Education
Vizient, Inc.
DISCLOSURE
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
Lubna Mazin, speaker for this educational activity, is a consultant for The Dedham Group and Orva.
Dmitry Walker, PharmD, MS, speaker for this educational activity, is an advisor for Pharmacosmos.
All relevant financial relationships listed for these individual(s) have been mitigated.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclaimer
Joint Accreditation Statement
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Pharmacists (CPE)
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance
- If the "Register/Take Course" tab is displayed instead of the "Obtain Credit" tab, you must first login to proceed with the credit claim process.
- This activity requires learners to confirm their attendance using an activity code. An Access Denied error message indicates that your attendance was not recorded via SMS text or QR code scanning.
Required Hardware/software
The Vizient CE Learner Portal is compatible with most modern web browsers (such as Firefox, Google Chrome, Microsoft Edge, Apple Safari) and can also be accessed with mobile devices.